SWTX SpringWorks Therapeutics Inc

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

STAMFORD, Conn., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted marketing authorization for OGSIVEO® ( nirogacestat ) , an oral gamma secretase inhibitor, as ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

STAMFORD, Conn., July 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted conditional marketing authorization for EZMEKLY® ( mirdametinib ) for the treatment of ...

- EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children ( ≥2 years ) with NF1-PN, a rare genetic disorder with debilitating symptoms - - EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults ...

- EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children ( ≥2 years ) with NF1-PN, a rare genetic disorder with debilitating symptoms - - EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults ...